Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
New York Post8d
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
NBC Connecticut3d
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in ...
U.S. News & World Report8d
Novo Nordisk Cuts Wegovy Prices, Following Similar Move by Zepbound-Maker Eli Lilly
Novo Nordisk Cuts Wegovy Prices, Following Similar Move by Zepbound-Maker Eli Lilly Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.
USA Today8d
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...